CLINICAL TRIALS PROFILE FOR NUVIGIL
✉ Email this page to a colleague
All Clinical Trials for NUVIGIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00078325 ↗ | Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) | Completed | Cephalon | Phase 3 | 2004-02-01 | The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit. |
| NCT00373672 ↗ | Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder | Completed | Cephalon | Phase 4 | 2006-08-01 | This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked. |
| NCT00373672 ↗ | Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder | Completed | National Alliance for Research on Schizophrenia and Depression | Phase 4 | 2006-08-01 | This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked. |
| NCT00373672 ↗ | Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder | Completed | Vanderbilt University | Phase 4 | 2006-08-01 | This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked. |
| NCT00373672 ↗ | Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder | Completed | Vanderbilt University Medical Center | Phase 4 | 2006-08-01 | This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NUVIGIL
Condition Name
Clinical Trial Locations for NUVIGIL
Trials by Country
Clinical Trial Progress for NUVIGIL
Clinical Trial Phase
Clinical Trial Sponsors for NUVIGIL
Sponsor Name
